Q-omics provides the consensus-scored MIR4778 profile across patient tissues and cancer cell-line models. MIR4778 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, MIR4778 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, MIR4778 RNA expression shows 10,062 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, LUSC, and THYM as cancer lineages where MIR4778 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4778 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4778 survival associations across molecular data types. MIR4778 RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4778 RNA expression–survival associations across cancer types. High MIR4778 expression shows unfavorable associations in STAD, LGG, ESCA, UCEC, KIRC and LUAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for MIR4778 RNA expression.
This table summarizes MIR4778 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4778. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4778 shows higher tumor expression in LUSC. The LUSC box plot shows higher MIR4778 RNA expression in tumor versus normal tissue (log2 FC = +0.059, t-test p = .042).
This table shows molecular features associated with MIR4778 in patient tissues and cancer cell lines. In patient samples, MIR4778 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
